Evidence map›Paper›PMID 41144114›Full record

ReviewEuropean journal of epidemiology2025

The early-onset cancer epidemics: evidence synthesis using the prospective cohort incident-tumor biobank method.

Shuji Ogino, Satoko Ugai, Tsuyoshi Hamada, Tomotaka Ugai

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shuji OginoProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 422B, Boston, MA, 02115, USA. sogino@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-3909-2323
Satoko UgaiProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 422B, Boston, MA, 02115, USA.
Tsuyoshi HamadaDepartment of Gastroenterology, University of Tokyo Hospital, Tokyo, Japan.
Tomotaka UgaiProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave., EBRC Room 422B, Boston, MA, 02115, USA. tugai@bwh.harvard.edu.

Funding

Spatial Immunopathological Epidemiology of Colorectal Adenoma-Carcinoma SpectrumR01CA248857 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jonathan Andrew Nowak, Shuji Ogino · 2020 to 2026
$6.6M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
Epigenetic Events and Colorectal Cancer EpidemiologyR01CA151993 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2010 to 2014
$2.6M
Integration of Immunology and Microbiology into Molecular Pathological Epidemiology of Colorectal CancerR50CA274122 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI UGAI, TOMOTAKA · 2023 to 2025
$506k
Integrating diet, lifestyle and tumor tissue molecular subtyping to study the role of adolescent calcium intake on the risk of early onset colorectal neoplasiaR21CA230873 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI OGINO, SHUJI, WU, KANA · 2018 to 2019
$427k
American Cancer Society CRP-24-1185864-01-PROFCancer Research UK C10674/A27140NIH HHS R01 CA151993NIH HHS R01 CA248857NIH HHS R21 CA230873NIH HHS R35 CA197735NIH HHS R50 CA274122
6 · The paper itself

Abstract

Tumors likely develop over years/decades, implying that assessing long-term exposure to risk factors is crucial in cancer epidemiology. An increasing trend of long-term risk factor exposures starting from early life since the mid-twentieth century appears to have contributed to the epidemics of early-onset cancer (EOC) worldwide. A rising incidence of EOC has been reported in various body sites such as the bone marrow, bile duct, breast, colorectum, esophagus, gallbladder, head and neck, kidney, liver, pancreas, stomach, and uterine corpus. To address an intractable gap between long-term exposure assessments and tumoral molecular/microenvironmental profiling in EOC research, here we describe a framework using the prospective cohort incident-tumor biobank method (PCIBM), which was recently conceptualized. The PCIBM enables prospective molecular pathological epidemiology research that can link long-term exposures with tumor pathogenic signatures. We illustrate this framework using the study of early-onset colorectal cancer (EOCRC). First, one recognizes overlaps of the characteristics of EOCRC and later-onset counterparts. Second, EOCRC tumoral, multi-omic, or microenvironmental features are discovered and replicated. Third, using the PCIBM, long-term exposure variables are examined in relation to the incidence of all-age colorectal cancer subtypes possessing EOCRC tumoral features. Fourth, identified putative risk factors are tested for EOCRC incidence. This framework, which has provided etiological insights and advanced our understanding of EOCRC pathogenesis, is widely applicable to EOC in various organs. In addition, this research modality with artificial intelligence-driven computational tools should be used in lifecourse and other prospective cohort studies to improve our knowledge of EOC pathogenesis.

Indexed as

Biological Specimen BanksColorectal NeoplasmsNeoplasmsAge of OnsetFemaleHumansIncidenceMaleMiddle AgedProspective StudiesRisk FactorsComplex multifactorial diseasesGenomicsImmunityMicrobiomePublic healthTranslational research

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.